Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
PRVA filing notifies proposed dispositions of common stock under Rule 144 and lists recent completed sales by a reporting person. The excerpt shows four reported sales by David Mountcastle: 23,887 shares on 12/12/2025, 5,361 on 02/26/2026, 7,697 on 02/27/2026, and 5,177 on 03/06/2026. It also lists 5,829 common shares tied to restricted stock vesting on 03/06/2026.
David Mountcastle reports proposed sale of 5,177 shares of common stock issued upon restricted stock vesting on 03/05/2026. The filing also lists recent open-market dispositions by Mr. Mountcastle in the past three months, including 23,887 shares on 12/12/2025, 5,361 shares on 02/26/2026, and 7,697 shares on 02/27/2026.
Privia Health Group, Inc. director Matthew Shawn Morris reported option exercises and related share sales. On February 26 and 27, 2026, he exercised stock options covering 24,338 shares of common stock at an exercise price of $2.00 per share.
He then sold 24,338 shares of common stock in open-market transactions at weighted average prices around $25.00 per share, executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owned 68,188 shares of common stock and held additional shares indirectly through a trust and Emerald Family, LLC.
Privia Health Group EVP & CFO David Mountcastle exercised fully vested stock options and sold shares under a pre-established Rule 10b5-1 trading plan. On February 26 and 27, he exercised options to receive common stock at an exercise price of $2.00 per share and then sold 13,058 shares of common stock in open-market transactions at weighted average prices around $25 per share, according to price ranges disclosed in the footnotes. After these transactions, he directly owns 172,909 shares of Privia common stock and indirectly owns 8,695 shares through his spouse.
David Mountcastle reported proposed sales of Common stock under a Form 144 filing.
The filing lists four option-originated Common share lots associated with option grant dates 08/28/2018 (3428 shares), 03/20/2019 (2699 shares), 12/04/2019 (998 shares), and 09/08/2020 (572 shares), each noted with a 02/27/2026 transaction date and labeled Cash.
The filing also discloses actual Common stock sales by David Mountcastle during the past three months: 23,887 shares sold on 12/12/2025 for $597,793.14 and 5,361 shares sold on 02/26/2026 for $134,030.87.
Privia Health Group, Inc. files its annual report describing a technology-driven physician-enablement business focused on value-based care across 24 states and the District of Columbia. The company supports 5,380 Privia Providers at over 1,300 locations, caring for more than 5.8 million patients.
Privia highlights its ACO performance, including $233.1 million of 2024 Medicare Shared Savings Program shared savings, a 32% increase over 2023, and per-member costs and utilization that were meaningfully below fee-for-service Medicare. The filing also outlines extensive healthcare, data privacy, and regulatory risks that could affect future operations.
PRVA filing reports a proposed sale of company common shares under a Form 144. The notice lists option-originated shares dated 02/26/2026 totaling 5,361 in four option blocks (1,893; 1,100; 1,668; 700). It records that David Mountcastle sold 23,887 shares on 12/12/2025 for $597,793.14.
Privia Health Group reported strong fourth quarter and full-year 2025 results, with every major operating and financial metric at or above the high end of its guidance ranges. Full-year revenue reached $2,122.8 million, up 22.3%, while net income rose 59.3% to $22.9 million.
Non-GAAP adjusted net income grew 30.8% to $127.7 million, and adjusted EBITDA increased 38.8% to $125.5 million. Implemented providers grew 12.3% to 5,380 and attributed lives rose 22.7% to 1,541,000, supporting practice collections of $3,470.5 million.
Cash generation was robust, with net cash provided by operating activities of $163.4 million and year-end cash of $479.7 million and no debt. For 2026, the company guides revenue to $2,350–$2,450 million and adjusted EBITDA to $145–$155 million, implying roughly 15–24% EBITDA growth and about 80% conversion to free cash flow.